HK Stock Market Move | JBM HEALTHCARE (02161) falls more than 12% with a year-on-year increase in net profit of about 1.9%, with a final dividend of 7.35 Hong Kong cents per share.
Healthcare Biotech (02161) fell over 12%, as of the time of writing, down 12.28% to 2 Hong Kong dollars, with a trading volume of 4.1982 million Hong Kong dollars.
JBM HEALTHCARE (02161) fell more than 12%, dropping by 12.28% to 2 Hong Kong dollars, with a turnover of 4.1982 million Hong Kong dollars as of the time of publication.
On the news front, JBM HEALTHCARE announced its annual performance for the year ending March 31, 2026, with revenue of approximately 835 million Hong Kong dollars, an increase of about 6.7% year-on-year; the company's attributable net profit to equity holders was approximately 201 million Hong Kong dollars, an increase of about 1.9% year-on-year; earnings per share were 24.63 Hong Kong cents, with a final dividend of 7.35 Hong Kong cents per share. The announcement stated that the revenue growth was mainly driven by the strong performance of the branded pharmaceuticals and branded Chinese medicine divisions, partially offset by the underperformance of health and wellness products.
Related Articles

HK Stock Market Move | CNBM (03323) rose more than 9% in early trading, with increases in fiberglass and electronic fabric prices being smoothly passed on. Institutions point out that CNBM has a leading advantage.

HK Stock Market Move | HENLIUS (02696) rose nearly 4% as the commercialization of the targeted therapy drugs BILDYOS and TUZEMTY in Canada began.

Guosen: How do multinational medical device companies view the Chinese market?
HK Stock Market Move | CNBM (03323) rose more than 9% in early trading, with increases in fiberglass and electronic fabric prices being smoothly passed on. Institutions point out that CNBM has a leading advantage.

HK Stock Market Move | HENLIUS (02696) rose nearly 4% as the commercialization of the targeted therapy drugs BILDYOS and TUZEMTY in Canada began.

Guosen: How do multinational medical device companies view the Chinese market?

RECOMMEND





